Research programme: CCR5/CXCR4 antagonists - Queen Mary College/King's College London

Drug Profile

Research programme: CCR5/CXCR4 antagonists - Queen Mary College/King's College London

Alternative Names: CCR5/CXCR4 antagonists research programme - Queen Mary College/King's College London

Latest Information Update: 10 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial sources
  • Developer BTG; Nonindustrial sources
  • Class
  • Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 30 Jul 1999 Available for licensing (http://www.btg.co.uk)
  • 30 Jul 1999 Rights acquired by British Technology Group
  • 12 Jul 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top